Catamaran acquires Salveo Specialty Pharmacy for $260 million Catamaran Corp. , a respected provider of pharmacy advantage management providers and technology solutions, today the completion announced, effective by January 2, 2015, of its previously disclosed acquisition of Salveo Specialty Pharmacy, for a purchase price of $260 million in money, subject to certain customary post-closing modifications compared . The purchase price was funded from Catamaran's existing cash balance. ‘This reaffirms our dedication to grow our specialty pharmacy features,’ said Mark Thierer, Chairman and CEO of Catamaran.’ Salveo Specialty Pharmacy is an independent specialty pharmacy business headquartered in St. Petersburg, Fla., with business procedures in NY and California . Salveo manages around $400 million in annual drug spend.

announced today that it has signed a non-binding Letter of Intent with the National Institute on Drug Abuse to carry out a U.S. Stage II scientific trial evaluating CPP-109, Catalyst’s formulation of vigabatrin, for the treating cocaine addiction.5 million in resources as part of the estimated $10 million trial cost. ‘We think that support from NIDA additional validates our enthusiasm of the potential for CPP-109 to help resolve the global problem of cocaine addiction,’ stated Patrick J. McEnany, CEO of Catalyst.’ ‘Presently, there are no FDA-approved medications to fight cocaine addiction,’ stated Dr. David McCann, Associate Director, Division of Medical and Pharmacotherapies Effects of Drug Abuse, NIDA.1 million cocaine abusers.’ SOURCE Catalyst Pharmaceutical Partners, Inc.